HomeCONGRESSInternational Congresses

International Congresses

View Category
Chronic Ischemic cardiopathy

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting,...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention...
Dr. Omar Tupayachi -
Learn More
Coronary Disease

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed...
Dr. Omar Tupayachi -
Learn More
Infrapatellar

TCT 2025 | LIFE-BTK: Three-Year Results of the Everolimus-Eluting Resorbable Scaffold in Infrapopliteal Lesions in Patients with Critical Limb Ischemia

Patients with chronic limb-threatening ischemia (CLTI) are among the most challenging in endovascular revascularization. While endovascular treatment...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

TCT 2025 | ANDES Trial: Short-Term DOAC vs. DAPT After Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) is an established alternative to chronic anticoagulation in patients with non-valvular...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

TCT 2025 | STORM-PE: Mechanical Thrombectomy with Penumbra Lightning+AC vs. Anticoagulation Alone in Intermediate-High Risk PE

Intermediate-high risk pulmonary embolism (PE) remains a therapeutic challenge. Anticoagulation is still the standard treatment, albeit with...
Dr. Omar Tupayachi -
Learn More
Chronic Ischemic cardiopathy

TCT 2025 | TUXEDO-2: Ultra-Thin Struts Versus Xience in Diabetic Patients with Multivessel Disease

It is well known that diabetic patients undergoing PCI often present with more extensive coronary artery disease,...
Dr. Andrés Rodríguez -
Learn More